Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis

References

• SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• HidalgoMPancreatic cancerN Engl J Med2010362171605161720427809
   PubMed Web of Science ®Google Scholar
• PetrushnkoWGundaraJSDe ReuverPRO’GradyGSamraJSMittalASystematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinomaHPB (Oxford)201618865266327485059
   PubMedGoogle Scholar
• GoldPFreedmanSOSpecific carcinoembryonic antigens of the human digestive systemJ Exp Med196512234674814953873
   PubMed Web of Science ®Google Scholar
• MolinaRBarakVvan DalenATumor markers in breast cancer-European Group on Tumor Markers recommendationsTumour Biol200526628129316254457
   PubMedGoogle Scholar
• GrunnetMSorensenJBCarcinoembryonic antigen (CEA) as tumor marker in lung cancerLung Cancer201276213814322153832
   PubMed Web of Science ®Google Scholar
• JuweidMSharkeyRMBehrTImproved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigenJ Clin Oncol1996144120912178648376
   PubMedGoogle Scholar
• NazliOBozdagADTansugTKirRKaymakEThe diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinomaHepatogastroenterology200047361750175211149048
   PubMedGoogle Scholar
• SatakeKChungYSYokomatsuHA clinical evaluation of various tumor markers for the diagnosis of pancreatic cancerInt J Pancreatol199071–325362081926
   PubMedGoogle Scholar
• HataSSakamotoYYamamotoYPrognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancerAnn Surg Oncol201219263664121863360
   PubMed Web of Science ®Google Scholar
• HamanakaYHamanakaSSuzukiMSialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 levelPancreas19961321601658829184
   PubMedGoogle Scholar
• TakasakiHUchidaETemperoMABurnettDAMetzgarRSPourPMCorrelative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patientsCancer Res1988486143514383162196
   PubMedGoogle Scholar
• ImaokaHMizunoNHaraKPrognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: a retrospective cohort studyPancreatology201616585986427256641
   PubMedGoogle Scholar
• LiuLXuHWangWA preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancerInt J Cancer201513692216222725273947
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGGroup PPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementInt J Surg20108533634120171303
   PubMed Web of Science ®Google Scholar
• WhitingPFRutjesAWWestwoodMEQUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studiesAnn Intern Med2011155852953622007046
   PubMed Web of Science ®Google Scholar
• MargulisAVPladevallMRiera-GuardiaNQuality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bankClin Epidemiol2014635936825336990
   PubMed Web of Science ®Google Scholar
• HaydenJACotePBombardierCEvaluation of the quality of prognosis studies in systematic reviewsAnn Intern Med2006144642743716549855
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• ParmarMKTorriVStewartLExtracting summary statistics to perform meta-analyses of the published literature for survival endpointsStat Med19981724281528349921604
   PubMed Web of Science ®Google Scholar
• WalterSDProperties of the summary receiver operating characteristic (SROC) curve for diagnostic test dataStat Med20022191237125612111876
   PubMed Web of Science ®Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trials revisitedContemp Clin Trials201545pt A13914526343745
   PubMed Web of Science ®Google Scholar
• RosmanASKorstenMAApplication of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testingAdv Med Sci200752768218217394
   PubMed Web of Science ®Google Scholar
• RoschTDittlerHJStrobelKEndoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: a blind reevaluation of videotapesGastrointest Endosc200052446947711023562
   PubMedGoogle Scholar
• VargasRNino-MurciaMTruebloodWJeffreyRBJrMDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformationsAJR Am J Roentgenol2004182241942514736675
   PubMed Web of Science ®Google Scholar
• LockerGYHamiltonSHarrisJASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancerJ Clin Oncol200624335313532717060676
   PubMed Web of Science ®Google Scholar
• TemperoMAUchidaETakasakiHBurnettDASteplewskiZPourPMRelationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancerCancer Res19874720550155033308077
   PubMed Web of Science ®Google Scholar
• KoopmannJFedarkoNSJainAEvaluation of osteopontin as biomarker for pancreatic adenocarcinomaCancer Epidemiol Biomarkers Prev200413348749115006928
   PubMed Web of Science ®Google Scholar
• KuhlmannKFvan TillJWBoermeesterMAEvaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancerCancer Epidemiol Biomarkers Prev200716588689117507610
   PubMedGoogle Scholar
• SimeoneDMJiBBanerjeeMCEACAM1, a novel serum biomarker for pancreatic cancerPancreas200734443644317446843
   PubMed Web of Science ®Google Scholar
• GuYLLanCPeiHYangSNLiuYFXiaoLLApplicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapyAsian Pac J Cancer Prev201516156569657326434876
   PubMedGoogle Scholar
• HaglundCTumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEABr J Cancer19865468979013467786
   PubMed Web of Science ®Google Scholar
• NiXGBaiXFMaoYLThe clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancerEur J Surg Oncol200531216416915698733
   PubMedGoogle Scholar
• Del FaveroGFabrisCPlebaniMCA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosisCancer1986578157615793456255
   PubMedGoogle Scholar
• LiaoQZhaoYPYangYCLiLJLongXHanSMCombined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic headHepatobiliary Pancreat Dis Int20076664164518086633
   PubMedGoogle Scholar
• BeniniLCavalliniGZordanDA clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancerPancreas19883161663163149
   PubMedGoogle Scholar
• DurakerNHotSPolatYHobekAGenclerNUrhanNCEACA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundiceJ Surg Oncol200795214214717262731
   PubMed Web of Science ®Google Scholar
• SakamotoKHagaYYoshimuraREgamiHYokoyamaYAkagiMComparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive systemGut19872833233293471687
   PubMed Web of Science ®Google Scholar
• Carpelan-HolmstromMLouhimoJStenmanUHAlfthanHHaglundCCEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancersAnticancer Res20022242311231612174919
   PubMed Web of Science ®Google Scholar
• HaasMLaubenderRPStieberPPrognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancerTumour Biol201031435135720480409
   PubMedGoogle Scholar
• KimJLeeYSHwangIKPostoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinomaJ Korean Med Sci201530325926325729247
   PubMed Web of Science ®Google Scholar
• LeeKJYiSWChungMJSerum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinomaYonsei Med J201354364364923549809
   PubMed Web of Science ®Google Scholar
• ReitzDGergerASeidelJCombination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancerJ Clin Pathol201568642743325759406
   PubMed Web of Science ®Google Scholar
• KandaMFujiiTTakamiHCombination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patientsSurg Today20144491692170124114022
   PubMed Web of Science ®Google Scholar
• TsavarisNKosmasCPapadoniouNCEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysisJ Chemother200921667368020071292
   PubMed Web of Science ®Google Scholar
• DistlerMPilarskyEKerstingSGrutzmannRPreoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – a retrospective tumor marker prognostic studyInt J Surg201311101067107224161419
   PubMed Web of Science ®Google Scholar
• PapadoniouNKosmasCGennatasKPrognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysisAnticancer Res2008281B54354918383900
   PubMedGoogle Scholar
• XuHXLiuLXiangJFPostoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinomaSurgery2017161237338427838102
   PubMed Web of Science ®Google Scholar
• SwetsJAMeasuring the accuracy of diagnostic systemsScience19882404857128512933287615
   PubMed Web of Science ®Google Scholar